ESSA Pharma Class Action Lawsuit
Analysis based on 17 articles · First reported Feb 03, 2025 · Last updated Mar 23, 2025
The market is impacted by the potential financial and reputational damage to ESSA Pharma due to the class action lawsuit, which could lead to a decrease in its stock value. Investors who purchased ESSA Pharma shares during the class period may seek recovery for their losses.
The Gross Law Firm has issued a notice to shareholders of ESSA Pharma regarding a pending class action lawsuit. The lawsuit alleges that ESSA Pharma made materially false and misleading statements between December 12, 2023, and October 31, 2024, concerning the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer. Specifically, the complaint claims that the combination had no clear efficacy benefit over enzalutamide alone, was less effective than represented, and that the M-E Combination Study was unlikely to meet its primary endpoint. Consequently, ESSA Pharma is accused of overstating masofaniten's clinical, regulatory, and commercial prospects. Shareholders are encouraged to contact The Gross Law Firm to potentially be appointed as lead plaintiff, with a deadline of March 25, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard